The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Francesca PalandriDuring the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to Francesca Palandri, University of Bologna, Bologna, IT. We asked: How do you manage ruxolitinib discontinuation syndrome?
Adverse events are often observed in patients following the discontinuation of treatment with ruxolitinib. In severe cases, patients may require hospitalization, and some cases can be fatal. Discontinuation syndrome reportedly occurs in ~15% of patients following ruxolitinib termination. Here, Francesca Palandri discusses how to minimise the risk of ruxolitinib discontinuation syndrome in clinical practice.
How do you manage ruxolitinib discontinuation syndrome?
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?